MDT

83.79

+1.09%↑

VEEV

220.31

+3.53%↑

A

106.16

+3.67%↑

WBA

11

+0.46%↑

CHE

586.66

+2.4%↑

MDT

83.79

+1.09%↑

VEEV

220.31

+3.53%↑

A

106.16

+3.67%↑

WBA

11

+0.46%↑

CHE

586.66

+2.4%↑

MDT

83.79

+1.09%↑

VEEV

220.31

+3.53%↑

A

106.16

+3.67%↑

WBA

11

+0.46%↑

CHE

586.66

+2.4%↑

MDT

83.79

+1.09%↑

VEEV

220.31

+3.53%↑

A

106.16

+3.67%↑

WBA

11

+0.46%↑

CHE

586.66

+2.4%↑

MDT

83.79

+1.09%↑

VEEV

220.31

+3.53%↑

A

106.16

+3.67%↑

WBA

11

+0.46%↑

CHE

586.66

+2.4%↑

Search

Coherus Biosciences Inc

Suletud

SektorTervishoid

1.08 2.86

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.03

Max

1.09

Põhinäitajad

By Trading Economics

Sissetulek

-40M

-51M

Müük

-17M

54M

P/E

Sektori keskmine

4.24

57.333

Aktsiakasum

-0.28

Kasumimarginaal

-93.632

Töötajad

228

EBITDA

-40M

-44M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+560.38% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

13M

130M

Eelmine avamishind

-1.78

Eelmine sulgemishind

1.08

Uudiste sentiment

By Acuity

41%

59%

149 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Coherus Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22. apr 2025, 20:55 UTC

Tulu

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22. apr 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Wall Street Rally -- Market Talk

22. apr 2025, 23:49 UTC

Market Talk

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22. apr 2025, 23:47 UTC

Peamised uudised

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22. apr 2025, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Woodside: No Change to Annual Guidance

22. apr 2025, 23:07 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22. apr 2025, 23:07 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22. apr 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22. apr 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22. apr 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy: Scarborough Energy Project 82% Complete

22. apr 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22. apr 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22. apr 2025, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22. apr 2025, 23:04 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22. apr 2025, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22. apr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22. apr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22. apr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy 1Q Revenue US$3.315 Billion

22. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22. apr 2025, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22. apr 2025, 22:31 UTC

Tulu

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22. apr 2025, 22:26 UTC

Peamised uudised

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22. apr 2025, 22:16 UTC

Peamised uudised

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22. apr 2025, 22:16 UTC

Market Talk

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22. apr 2025, 22:04 UTC

Peamised uudised

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22. apr 2025, 21:42 UTC

Tulu

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22. apr 2025, 21:21 UTC

Peamised uudised
Tulu

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22. apr 2025, 21:19 UTC

Peamised uudised

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Coherus Biosciences Inc Prognoos

Hinnasiht

By TipRanks

560.38% tõus

12 kuu keskmine prognoos

Keskmine 7 USD  560.38%

Kõrge 7 USD

Madal 7 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Coherus Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.01 / 1.07Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

149 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.